Condition: Impaired Hepatic Function · Sponsor: Zealand Pharma
This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities. The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.
This description comes directly from the study's public registry record.
Clinical Trial Information Desk · +4588773600 · clinicaltrials@zealandpharma.com
Always discuss trial participation with your own doctor first.
| Centrum Badan Klinicznych Piotr Napora Lekarze sp.p. | Wroclaw, Poland, Poland | Recruiting |
| Summit Clinical Research s.r.o. | Bratislava, Bratislava Region, Slovakia | Recruiting |
| Summit Clinical Research s.r.o. | Malacky, Malacky, Slovakia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07682818